Pirtobrutinib显示,作为一线CLL/SLL治疗,安全性较强,答复率较高,与ibrutinib相比,这种治疗很有前途。 Pirtobrutinib shows promise as a first-line CLL/SLL treatment with better safety and high response rates vs. ibrutinib.

在2025年ASH会议上提出的第3阶段试验中,pirtobrutinib显示,在未经治疗和复发/抗病的CLL/SLL病人中,与ibrutinib患者相比,总体答复率不高,治疗性个人的答复率较高,安全情况更有利,包括低度的早发性颤动和高血压,这表明有可能被广泛用作一线治疗。 In a phase 3 trial presented at the 2025 ASH meeting, pirtobrutinib showed non-inferior overall response rates compared to ibrutinib in untreated and relapsed/refractory CLL/SLL patients, with higher response rates in treatment-naive individuals and a more favorable safety profile, including lower rates of atrial fibrillation and hypertension, suggesting potential for broader use as a first-line therapy.